论文部分内容阅读
目的观察神经发育疗法(neurodevelopmental treat ment,NDT)对脑瘫(cerebral palsy,CP)患儿血清促红细胞生成素(erythropoietin,EPO)水平的影响。方法用双抗体夹心ABC-ELISA法分别检测CP组和CP高危因素新生儿(新生儿病例组)血清EPO水平变化,并分别与其对照组比较。结果CP组NDT治疗后血清EPO高于对照组和NDT治疗前(P均<0.01),NDT治疗前血清EPO水平与CP对照组比较无统计学差异(P>0.05);新生儿病例组血清EPO水平明显高于新生儿病例对照组(P<0.01)。结论EPO可以作为评估神经发育疗法疗效的生物学指标。
Objective To observe the effect of neurodevelopmental treatment (NDT) on serum erythropoietin (EPO) in children with cerebral palsy (CP). Methods Serum levels of EPO in neonates with newborn (CP group) and high risk group (CP) were detected by double antibody sandwich ABC-ELISA. The levels of serum EPO were compared with those of the control group respectively. Results Compared with control group and NDT group, EPO level in ND group was significantly higher than that in ND group (P <0.01). There was no significant difference in serum EPO level between ND group and ND group before NDT treatment (P> 0.05) The level was significantly higher than the neonatal case control group (P <0.01). Conclusion EPO can be used as a biological indicator to evaluate the efficacy of neurodevelopmental therapy.